Amarin (AMRN) News Today $0.49 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Amarin announces to present additional analysis from REDUCE-IT outcomes trialNovember 12, 2024 | markets.businessinsider.comAmarin (NASDAQ:AMRN) Announces Earnings Results, Misses Expectations By $0.02 EPSAmarin (NASDAQ:AMRN - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.15%. The firm had revenue of $42.30 million during the quarter, compared to analysts' expectations of $43.82 million. During the same quarter in the prior year, the firm posted ($0.05) EPS.November 2, 2024 | marketbeat.comAmarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ...November 1, 2024 | finance.yahoo.comAmarin Corporation plc (NASDAQ:AMRN) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comAmarin sees current cash, investments, other assets to support operationsOctober 31, 2024 | markets.businessinsider.comAmarin Corporation: Q3 Highlights and Future OutlookOctober 31, 2024 | markets.businessinsider.comAmarin Reports Third Quarter 2024 Financial Results and Provides Business UpdateOctober 31, 2024 | markets.businessinsider.comAmarin Plc (AMRN) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | finance.yahoo.comAmarin (AMRN) Scheduled to Post Earnings on WednesdayAmarin (NASDAQ:AMRN) will be releasing earnings after the market closes on Wednesday, October 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=632333)October 23, 2024 | marketbeat.comAmarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...October 10, 2024 | uk.finance.yahoo.comAmarin Corp (NASDAQ:AMRN) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comZacks Research Brokers Lift Earnings Estimates for Amarin Co. plc (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of Amarin in a report issued on Tuesday, October 1st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn (October 4, 2024 | marketbeat.comAmarin Announces Two Upcoming Investor EventsOctober 1, 2024 | markets.businessinsider.comHere's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn SituationSeptember 18, 2024 | finance.yahoo.comAura Biosciences: Highly Derisked Late-Stage Eye Cancer CompanySeptember 17, 2024 | seekingalpha.comResearch Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) MeetingSeptember 9, 2024 | globenewswire.comAmarin Corp PLC (EH3A.DU)September 4, 2024 | sg.finance.yahoo.comAmarin Co. plc Expected to Post Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Free Report) - Analysts at Zacks Research raised their Q3 2024 earnings per share estimates for Amarin in a research report issued on Wednesday, August 21st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.05) per shaAugust 26, 2024 | marketbeat.comLatest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressAugust 22, 2024 | globenewswire.comAmarin Corp (NASDAQ:AMRN) Stock Quotes, Forecast and News SummaryAugust 17, 2024 | benzinga.comAmarin Co. plc (NASDAQ:AMRN) CEO Aaron Berg Buys 160,000 SharesAugust 6, 2024 | insidertrades.comAmarin Co. plc (NASDAQ:AMRN) CEO Purchases $102,400.00 in StockAmarin Co. plc (NASDAQ:AMRN - Get Free Report) CEO Aaron Berg acquired 160,000 shares of the stock in a transaction dated Friday, August 2nd. The shares were purchased at an average price of $0.64 per share, for a total transaction of $102,400.00. Following the completion of the transaction, the chief executive officer now owns 805,380 shares of the company's stock, valued at approximately $515,443.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.August 5, 2024 | marketbeat.comAmarin’s Stock Maintains Hold Rating Amidst Revenue Highs and Market ChallengesAugust 5, 2024 | markets.businessinsider.comBrokers Set Expectations for Amarin Co. plc's FY2024 Earnings (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Amarin in a report issued on Thursday, August 1st. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will earn ($0.13) per shareAugust 5, 2024 | marketbeat.comFY2026 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Decreased by AnalystAmarin Co. plc (NASDAQ:AMRN - Free Report) - Analysts at Zacks Research reduced their FY2026 earnings per share (EPS) estimates for shares of Amarin in a report released on Tuesday, July 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earninAugust 1, 2024 | marketbeat.comAmarin’s Sell Rating Upheld Amid Revenue Concerns and Market Access ChallengesAugust 1, 2024 | markets.businessinsider.comAmarin appoints new CEO and grants stock optionsJuly 31, 2024 | investing.comAmarin Corporation plc (AMRN) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | seekingalpha.comAmarin Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 31, 2024 | stockhouse.comAmarin Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 31, 2024 | globenewswire.comTraders Purchase Large Volume of Call Options on Amarin (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Get Free Report) was the recipient of unusually large options trading on Monday. Stock investors bought 2,899 call options on the stock. This is an increase of approximately 399% compared to the typical volume of 581 call options.July 29, 2024 | marketbeat.com3 Breakthrough Stocks Under $10 Set for Massive UpsideJuly 29, 2024 | investorplace.comAmarin Corporation plc's (NASDAQ:AMRN) Intrinsic Value Is Potentially 29% Above Its Share PriceJuly 22, 2024 | finance.yahoo.comAmarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in PortugalJuly 17, 2024 | globenewswire.comAmarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024July 17, 2024 | globenewswire.comAmarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)July 8, 2024 | globenewswire.comAmarin (NASDAQ:AMRN) Rating Lowered to Hold at StockNews.comStockNews.com downgraded shares of Amarin from a "buy" rating to a "hold" rating in a research note on Thursday.July 4, 2024 | marketbeat.comQ3 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Reduced by AnalystAmarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Amarin in a research note issued on Wednesday, June 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earningsJuly 1, 2024 | marketbeat.comAmarin Co. plc (NASDAQ:AMRN) Sees Significant Growth in Short InterestAmarin Co. plc (NASDAQ:AMRN - Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 19,020,000 shares, a growth of 20.3% from the May 31st total of 15,810,000 shares. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 12.8 days.June 30, 2024 | marketbeat.comAmarin (NASDAQ:AMRN) Downgraded by StockNews.com to HoldStockNews.com downgraded Amarin from a "buy" rating to a "hold" rating in a research note on Tuesday.June 25, 2024 | marketbeat.comAmarin (NASDAQ:AMRN) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Amarin in a research report on Tuesday.June 18, 2024 | marketbeat.comAmarin (NASDAQ:AMRN) Raised to Buy at StockNews.comStockNews.com upgraded shares of Amarin from a "hold" rating to a "buy" rating in a research report on Monday.June 17, 2024 | marketbeat.comLA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in BangkokJune 7, 2024 | globenewswire.comAmarin Board of Directors Announces CEO TransitionJune 4, 2024 | globenewswire.comAmarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.May 28, 2024 | globenewswire.comZacks Research Weighs in on Amarin Co. plc's FY2024 Earnings (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Free Report) - Zacks Research lifted their FY2024 earnings estimates for Amarin in a research report issued on Wednesday, May 22nd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of ($0.16) per share for theMay 24, 2024 | marketbeat.comAmarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 6, 2024 | globenewswire.comAmarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comQ2 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Reduced by Zacks ResearchAmarin Co. plc (NASDAQ:AMRN - Free Report) - Research analysts at Zacks Research lowered their Q2 2025 EPS estimates for shares of Amarin in a research report issued to clients and investors on Tuesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical companMay 3, 2024 | marketbeat.comAmarin (NASDAQ:AMRN) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPSAmarin (NASDAQ:AMRN - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. During the same period in the previous year, the company posted ($0.04) EPS.May 2, 2024 | marketbeat.com Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide AMRN Media Mentions By Week AMRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRN News Sentiment▼-1.000.45▲Average Medical News Sentiment AMRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRN Articles This Week▼02▲AMRN Articles Average Week Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Heron Therapeutics News Generation Bio News Y-mAbs Therapeutics News Rapport Therapeutics News Tyra Biosciences News Evolus News Relay Therapeutics News Prothena News Pliant Therapeutics News Cronos Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
